Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

France's Atos said on Wednesday its sales returned to growth in the third quarter, beating expectations as the loss-making IT consulting firm strives to regain markets' trust by carrying out a costly split-up plan.

Atos returns to sales growth in Q3, beats market expectations

Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseases Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseases

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

Acorda Therapeutics

Atara Biotherapeutics

PAVmed

Xeris Biopharma Holdings

Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week

Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO

Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment

Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers

Atossa Genetics (NASDAQ:ATOS ) Q2 Results Conference Call July 27, 2022 2:00 AM ET Company Participants Conference Call Participants Amit Harchandani - Citi Operator Thank you all for standing by and welcome to the Atossa First Half 2022 Results. At this time all participants are in a listen-only mode.

Atossa Therapeutics, Inc. (ATOS) Q2 2022 Results - Earnings Call Transcript

PHX Minerals

Kintara Therapeutics

Here's what you need to know about buying penny stocks in 2022 The post Best Tips for Buying Penny Stocks in 2022? 3 to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Tips for Buying Penny Stocks in 2022? 3 to Know

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations.

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the Q2 Investor Summit Conference. The conference is being held on May 3 – 4, 2022 at the Westin New York Grand Central Hotel.

Atossa Therapeutics to Present at the Q2 Investor Summit Conference

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that management will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held March 28-30, 2022.

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

Clovis Oncology

Eos Energy Enterprises

Which penny stocks are on your watchlist for next week? The post Hot Penny Stocks to Watch Next Week?

Hot Penny Stocks to Watch Next Week? 3 For Your List

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that the U.S. Patent and Trademark office has issued a new patent further strengthening Atossa's intellectual property in its proprietary therapy Endoxifen, which is under development for breast cancer and other breast conditions.

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) --  Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments.

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders:

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide.

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses.

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

Camber Energy

Kosmos Energy

Are these penny stocks on your list of small-caps to watch right now? The post 3 Penny Stocks to Watch With Bullish Sentiment Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Atossa Genetics Stock (ATOS)